<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196869</url>
  </required_header>
  <id_info>
    <org_study_id>201708112121</org_study_id>
    <nct_id>NCT03196869</nct_id>
  </id_info>
  <brief_title>the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer</brief_title>
  <official_title>Phase II Clinical Randomized Study of the Effect of Chronomodulated Chemotherapy Followed by Concurrent IMRT Chemo-radiotherapy on the Dendritic Cells Subsets and Immunity in the Treatment of Advanced Nasopharyngeal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guiyang Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guiyang Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to observe and compare the effect of docetaxel plus lobaplatin induction
      chemotherapy combined with lopoplatin chemoradiotherapy and TPF induction chemotherapy
      combined with cisplatin chemoradiotherapy on dendritic cells subsets in the treatment of
      locally advanced head and neck squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TPF program is currently the local advanced head and neck squamous cell carcinoma commonly
      used inducing chemotherapy, cisplatin is the preferred drug for the same period
      chemotherapy.Dendritic cells (DC) play an essential role in the induction and regulation of
      immune responses.The effect of radiation and chemotherapy is closely related to the patients'
      immune function.In this study, Phase II clinical trials were performed. Patients with locally
      advanced head and neck squamous cell carcinoma were randomly divided into experimental group
      and control group. The trial group was treated with docetaxel + lorosine-induced chemotherapy
      combined with lorplatin concurrent radiotherapy and chemotherapy. The control group was
      treated with TPF Cisplatin concurrent chemotherapy, observed the relationship between
      dendritic cells subsets and clinical prognosis of patients, to provide a new method for the
      treatment of locally advanced nasopharyngeal carcinoma and technical support
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2017</start_date>
  <completion_date type="Anticipated">August 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 12, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dendritic cell subgroup changes of Participants</measure>
    <time_frame>termination of treatment, 3 months after treatment</time_frame>
    <description>By flow cytometry detection of two groups of peripheral blood dendritic cells subsets and lymphocyte subpopulation changes before and after the radiation and chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with curative effect</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate the immediate effect at 1year after Concurrent chemo-radiotherapy by RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>5 year</time_frame>
    <description>To assess and record nausea, vomiting, oral mucositis, diarrhea and other adverse drug reactions by CTC 4.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate the Progression-free survival at five years after Concurrent chemo-radiotherapy by RECIST.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate the Overall survival at five years after Concurrent chemo-radiotherapy by RECIST</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Locally Advanced Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Chrono-chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy;Delivery time is different from the control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine intravenous drip</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>control group:Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chrono-chemotherapy</intervention_name>
    <description>Chrono-chemotherapy+concurrent radiochemotherapy</description>
    <arm_group_label>Chrono-chemotherapy group</arm_group_label>
    <other_name>Experimental group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Routine intravenous drip</intervention_name>
    <description>Routine intravenous drip-chemotherap</description>
    <arm_group_label>Routine intravenous drip</arm_group_label>
    <other_name>control group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction Chrono-chemotherapy</intervention_name>
    <description>Experimental group:docetaxel,cisplatin,5-FU</description>
    <arm_group_label>Chrono-chemotherapy group</arm_group_label>
    <other_name>chronological dosage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction Routine-chemotherapy</intervention_name>
    <description>control group:docetaxel,cisplatin,5-FU</description>
    <arm_group_label>Routine intravenous drip</arm_group_label>
    <other_name>Conventional drug delivery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin chrono-chemotherapy</intervention_name>
    <description>Experimental group: cisplatin chrono-chemotherapy</description>
    <arm_group_label>Chrono-chemotherapy group</arm_group_label>
    <other_name>cisplatin Conventional drug delivery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin routine-chemotherapy</intervention_name>
    <description>control group:cisplatin routine-chemotherapy</description>
    <arm_group_label>Routine intravenous drip</arm_group_label>
    <other_name>cisplatin Conventional drug delivery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>control group is similar to Experimental group</description>
    <arm_group_label>Chrono-chemotherapy group</arm_group_label>
    <arm_group_label>Routine intravenous drip</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. initial treatment of advanced nasopharyngeal carcinoma Ⅲ-Ⅳ patients with
             pathologically confirmed (according to 2010 UICC staging, T3-4, N0-3), without
             evidence of distant metastasis (M0). Have measurable tumor lesions.

          2. KPS≥70 points.

          3. the age of 18-70 years old, male or female.

          4. no major organ dysfunction; normal bone marrow function (WBC ≥4.0 × 109 / L, platelets
             ≥100 × 109 / L, hemoglobin ≥90g / L), normal liver function (total bilirubin, alanine
             aminotransferase, aspartate aminotransferase ≤1.5 times the upper limit of normal),
             normal renal function (creatinine ≤ 1.5 times upper limit of normal).

          5. understand this study and signed informed consent

        Exclusion Criteria:

          1. Three months in the use of Chinese herbal medicine or immune modulators

          2. distant metastasis.

          3. who had received prior chemotherapy.

          4. patients have physical or mental illness, and by researchers believe that patients can
             not be completely or fully understood in this study possible complications.

          5. pregnancy (via the urine or serum β-HCG test confirmed) or during lactation. serious
             complications, such as uncontrolled hypertension, heart failure, diabetes and so on.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Jin, Bachelor</last_name>
    <role>Study Chair</role>
    <affiliation>Guizhou Provincial Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Jin, Bachelor</last_name>
    <phone>0851-86512802</phone>
    <email>jinf8865@yeah.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan Li, Bachelor</last_name>
    <phone>0851-86512802</phone>
    <email>1348330985@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Jin, Bachelor</last_name>
      <phone>0851-86512802</phone>
      <email>jinf8865@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Weili Wu, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinhua Long, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuanyuan Li, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiuyun Gong, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoxiao Chen, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Li, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guiyang Medical University</investigator_affiliation>
    <investigator_full_name>Feng Jing</investigator_full_name>
    <investigator_title>Head and neck cancer director, chief researcher, clinical professor</investigator_title>
  </responsible_party>
  <keyword>NPC peripheral blood dendritic cell chronic-chemotherap</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

